Financial Performance - The company reported a net profit attributable to shareholders of the parent company of -316.24 million yuan for the year 2021, with a cumulative undistributed profit of -593.90 million yuan at year-end, resulting in no profit distribution for the year[6]. - In 2021, the company's operating revenue decreased by 23% to ¥854,223,148.51 compared to ¥1,109,430,046.82 in 2020[30]. - The net profit attributable to shareholders turned from a profit of ¥32,003,001.58 in 2020 to a loss of ¥316,244,434.80 in 2021, representing a decline of 1,088.17%[30]. - The company reported a basic earnings per share of -¥0.64 in 2021, down from ¥0.07 in 2020, reflecting a decrease of 1,014.29%[27]. - The weighted average return on equity fell to -14.03% in 2021, a decrease of 15.38 percentage points from 1.35% in 2020[27]. - The total assets decreased by 18.31% to ¥3,102,482,555.59 at the end of 2021, down from ¥3,797,965,909.49 at the end of 2020[30]. - The company reported a total loss of CNY 352.63 million in profit before tax, compared to a profit of CNY 17.51 million in the previous year[111]. - The company achieved operating revenue of CNY 854 million in 2021, a year-on-year decrease of 23%[41]. - The net profit attributable to shareholders was a loss of CNY 316.24 million, while sales collections increased by 26% to CNY 1.107 billion[41]. Cash Flow and Expenses - The company's cash flow from operating activities improved, with a net cash flow of ¥81,368,872.18 in 2021, compared to a negative cash flow of ¥75,524,827.22 in 2020[30]. - The net operating cash flow improved to CNY 81.37 million, a significant increase of CNY 157 million compared to the previous year's negative cash flow[41]. - The sales expense increased by 35.29% to CNY 782.22 million, reflecting the company's response to market challenges due to the pandemic[111]. - Research and development expenses decreased by 42.01% to CNY 25.19 million, indicating a shift in investment strategy[111]. - The overall cost of raw materials decreased by 2.62%, reflecting improved procurement strategies and cost management[134]. - The company reported a decrease in credit impairment losses by 94.01 million RMB, attributed to a reduction in accounts receivable[114]. Market and Strategic Developments - The company plans to enhance its marketing strategies and improve internal management to stabilize market share amid ongoing economic challenges[31]. - The company has outlined various risks it may face in its operations, including industry policy risks and fluctuations in raw material supply and prices[9]. - The company is focusing on market restructuring and receivables management to improve its financial structure for future growth[111]. - The company has established a governance structure to ensure compliance with state-owned enterprise regulations following its return to the state-owned system[54]. - The company has established a collaborative distribution model, enhancing market penetration through partnerships with wholesalers and retailers[86]. Research and Development - The company has received 2 invention patents and was awarded the second prize for technological progress in Shanxi Province, indicating a strong focus on R&D[49]. - The company has published over 200 academic papers, including 16 in SCI journals, demonstrating its strong research capabilities[96]. - The company has multiple R&D projects, with the highest investment being 363.22 million RMB for the Liuwedi Huang series[193]. - The company’s R&D direction focuses on new dosage forms and therapeutic areas for existing products[191]. - The company has established a "production-academia-research" model to enhance product advantages and modern medical theory research[162]. Product and Market Position - The company has 36 products included in the National Essential Medicines List and 61 products in the National Medical Insurance Directory[76]. - The core products, including Gui Ling Ji and Ding Kun Dan, are recognized as national intangible cultural heritage[79]. - The company aims to enhance the quality of traditional Chinese medicine by adhering to strict GMP standards and traditional production methods[73]. - The company has expanded its product offerings by introducing the "Body Cultivation Niuhuang" series to meet diverse consumer needs[130]. - The company’s products are not included in the national essential drug list but are part of provincial medical insurance directories[170]. Industry Trends and Government Policies - The pharmaceutical manufacturing industry saw a 24.8% increase in value added compared to the previous year, with monthly industrial value added growth exceeding 8% throughout 2021[57]. - The government emphasized the importance of traditional Chinese medicine in combating COVID-19, integrating it into treatment protocols[62]. - The ongoing urbanization and rising disposable income in China are expected to further boost the demand for traditional Chinese medicine[62]. - In 2021, over 500 new policies related to the pharmaceutical industry were issued by the national government, significantly impacting the sector[64]. Compliance and Governance - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has received a standard unqualified audit report from Lianda Certified Public Accountants[5]. - The company’s board of directors and supervisory board members have all attended the board meeting, ensuring the authenticity and completeness of the annual report[4]. - The company is closely monitoring changes in medical policies to adapt its strategies accordingly[76].

广誉远中药股份有限公司 2021 年第三季度报告 单位：元 币种：人民币 证券代码：600771 证券简称：广誉远 广誉远中药股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一）主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|----------------------------------------|-----------------|-------------------- ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 432,558,335.54, a decrease of 13.22% compared to the same period last year[24]. - The net profit attributable to shareholders of the listed company was CNY 43,440,688.96, down 210.69% year-on-year[24]. - The net profit after deducting non-recurring gains and losses was CNY 26,927,054.37, a decline of 340.88% compared to the previous year[24]. - The total assets at the end of the reporting period were CNY 3,797,965,909.49, a decrease of 9.07% from the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were CNY 2,412,130,935.42, down 1.99% from the end of the previous year[24]. - Basic earnings per share for the first half of 2021 were CNY -0.10, a decrease of 211.11% year-on-year[25]. - The diluted earnings per share were also CNY -0.10, reflecting the same percentage decrease[25]. - The weighted average return on net assets was -2.01%, a decrease of 3.84 percentage points compared to the previous year[25]. - The comprehensive gross margin decreased by 8.38 percentage points year-on-year, influenced by changes in the sales proportion of different gross margin products, rising raw material prices, and increased sales support for key commercial clients[29]. - The basic (diluted) earnings per share decreased by 211.11% year-on-year, mainly due to the decline in net profit during the reporting period[29]. Cash Flow and Assets - The net cash flow from operating activities was CNY -126,559,912.53, with no applicable comparison[24]. - The net cash flow from operating activities increased by 155.10 million yuan compared to the same period last year, primarily due to a 226.87 million yuan increase in cash received from sales of goods, representing a growth of 66.37%[29]. - The company reported a total asset of 3.453 billion yuan and a net asset attributable to shareholders of 2.364 billion yuan as of June 30, 2021[73]. - Cash and cash equivalents decreased by 55.50% to CNY 175,191,825.98, primarily due to the redemption of bank acceptance bills[112]. - Accounts receivable decreased by 8.94% to CNY 1,420,231,515.01, maintaining a stable proportion of total assets at 41.13%[112]. - Inventory decreased by 7.29% to CNY 336,239,051.09, representing 9.74% of total assets[112]. Market and Industry Trends - The pharmaceutical manufacturing industry in China achieved an operating income of CNY 1,404.69 billion, representing a year-on-year growth of 28.0%[51]. - The total profit for the pharmaceutical manufacturing sector reached CNY 300.04 billion, with a remarkable year-on-year increase of 88.88%[51]. - The Chinese pharmaceutical manufacturing industry's industrial added value grew by 29.6% year-on-year, outperforming the overall industrial growth rate by 13.7 percentage points[51]. - The market for traditional Chinese medicine manufacturing is projected to reach CNY 75.3 billion in 2021, showing an upward trend[54]. Product and R&D Development - The company has 104 drug registration certificates, 1 health food license, and 1 liquor license, with 36 drugs listed in the National Essential Medicines List (2018 edition)[37]. - The company’s core products, including Gui Ling Ji and Ding Kun Dan, have been recognized as national intangible cultural heritage, highlighting the company's historical significance and brand image[37]. - The company is engaged in the production and sales of traditional Chinese medicine, with its core business divided into traditional Chinese medicine, premium Chinese medicine, and health wine[37]. - The company has increased its R&D investment in the "Zhiliao Youfang APP" project by CNY 2,591,000, reflecting a significant increase of 959.00%[112]. - The company has 26 ongoing research projects and has published over 200 related papers, including 13 in SCI journals[64]. - The company owns 20 patents, with 2 new patents successfully applied for during the reporting period[66]. Sales and Marketing Strategies - The company has strengthened its marketing strategies, including increasing sales support for key commercial clients and enhancing consumer education activities[72]. - The company is actively expanding its sales channels through various models, including cooperative distribution and agency sales[49]. - E-commerce sales during the 618 mid-year promotion increased by 129% compared to the same period in 2020, with overall sales up by 46% in the reporting period[81]. - The company added 31 new terminal stores and 14 new agents, bringing the total number of terminal stores to nearly 300 by June 30, 2021[82]. - The OTC division optimized terminal sales strategies, achieving a 50% year-on-year increase in traditional Chinese medicine receivables and improved inventory management[80]. Environmental and Compliance Measures - The company has established a wastewater treatment facility with a processing capacity of 15m³/h, ensuring that all pollutants are discharged within the standards[150]. - The company has implemented a third-party environmental monitoring program to ensure compliance with discharge standards[151]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental bureau[154]. - The company's pollution control facilities are reported to be in good operating condition, with all pollutants meeting discharge standards[158]. Governance and Management Changes - The company held its first extraordinary shareholders' meeting on January 21, 2021, where two proposals were approved, including changes to the company's registered address and amendments to certain articles of association[139]. - The 2020 annual shareholders' meeting was held on May 28, 2021, approving seven proposals, including the 2020 annual work report and financial budget for 2021[140]. - There were changes in senior management, with Yang Hongfei resigning as director and executive vice president, and Zheng Yanli resigning as director and vice president due to work changes[143]. - The company has committed to maintaining independence from its controlling shareholder in terms of assets, personnel, and operations[165]. Risks and Challenges - The company faces risks from intensified industry policies and market competition, which may lead to significant changes in operational models and competitive landscapes due to ongoing healthcare reforms and regulatory measures[126]. - The company is actively managing accounts receivable risks, which are high due to long payment cycles in the medical industry, and is implementing stricter collection policies to improve cash flow[127]. - The company is addressing raw material supply and price volatility risks by enhancing inventory management and establishing strategic partnerships with suppliers to ensure stable pricing and quality[131]. - The company emphasizes quality control in its production processes to mitigate quality safety risks, adhering to national regulations and enhancing training for staff to prevent quality incidents[136].

Financial Performance - Operating revenue for the period was CNY 190,029,084.46, representing a decline of 15.51% year-on-year[9] - Net profit attributable to shareholders was CNY 5,169,889.88, down 81.25% compared to the same period last year[9] - Basic and diluted earnings per share were both CNY 0.01, a decrease of 83.33% year-on-year[9] - Total profit decreased by 74.61% to ¥7,019,061.56 from ¥27,641,313.24, primarily due to a 15.51% decline in sales revenue[26] - Net profit fell by 82.15% to ¥4,800,646.21 from ¥26,892,619.40, attributed to changes in product sales structure and increased market investment[26] - The company reported a gross profit margin of approximately 1.2% in Q1 2021, compared to 11.5% in Q1 2020[63] - The company reported an operating profit of ¥7,328,585.74 for Q1 2021, a decrease of 75.1% compared to ¥29,204,319.48 in Q1 2020[63] Cash Flow - The net cash flow from operating activities was CNY -31,589,979.57, an improvement from CNY -96,876,641.76 in the previous year[9] - Operating cash flow increased by ¥65,286,700.00, mainly due to higher cash receipts from sales compared to the previous year[31] - The cash inflow from operating activities in Q1 2021 was CNY 267,069,586.06, an increase of 43.7% compared to CNY 185,803,566.25 in Q1 2020[75] - The cash outflow from operating activities in Q1 2021 was CNY 298,659,565.63, compared to CNY 282,680,208.01 in Q1 2020, resulting in a net cash flow from operating activities of -CNY 31,589,979.57, an improvement from -CNY 96,876,641.76 in the previous year[75] - The cash inflow from investment activities in Q1 2021 was CNY 588,583.25, while the cash outflow was CNY 7,980,658.10, leading to a net cash flow from investment activities of -CNY 7,392,074.85, an improvement from -CNY 14,832,202.67 in Q1 2020[78] - The cash inflow from financing activities in Q1 2021 was CNY 207,447,616.31, a decrease of 31.1% from CNY 301,138,386.12 in Q1 2020[78] - The cash outflow from financing activities in Q1 2021 was CNY 271,047,332.87, compared to CNY 207,418,863.85 in Q1 2020, resulting in a net cash flow from financing activities of -CNY 63,599,716.56, a decline from CNY 93,719,522.27 in the previous year[78] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,608,275,494.42, a decrease of 4.99% compared to the end of the previous year[9] - Cash and cash equivalents decreased by 49.41% to ¥199,148,222.89 from ¥393,671,975.59 due to repayment of bank loans and maturity of bank acceptance bills[21] - Accounts receivable financing decreased by 41.96% to ¥77,004,280.70 from ¥132,681,691.33 as a result of endorsement transfer and discounting of bank acceptance bills[22] - Other receivables increased by 72.53% to ¥256,547,340.93 from ¥148,699,851.97, driven by increased market reserve funds and other business transactions[25] - Long-term equity investments decreased from ¥12,467,844.91 to ¥12,052,627.44, a decline of approximately 3.34%[43] - Fixed assets decreased from ¥768,688,760.90 to ¥760,533,009.03, a decline of approximately 1.51%[43] - Current liabilities decreased from ¥1,272,065,524.09 to ¥1,076,911,157.31, a decline of approximately 15.29%[46] - Total liabilities decreased from ¥1,328,313,314.14 to ¥1,133,822,252.86, a decline of approximately 14.68%[46] - Owner's equity increased from ¥2,469,652,595.35 to ¥2,474,453,241.56, an increase of approximately 0.15%[49] - The total liabilities and owner's equity decreased from ¥3,797,965,909.49 to ¥3,608,275,494.42, a decline of approximately 4.98%[49] - The company reported a significant reduction in employee compensation liabilities from ¥11,789,632.05 to ¥6,739,602.66, a decrease of approximately 42.00%[46] Research and Development - Development expenses surged by 1,218.95% to ¥3,543,487.51 from ¥268,659.73 due to increased R&D investments in clinical studies and product development[25] - Research and development expenses decreased to ¥3,635,897.56 in Q1 2021 from ¥6,154,917.28 in Q1 2020, a reduction of 40.8%[61] Market and Investment Strategy - Marketing expenses increased by 2.11 percentage points as the company intensified market investments[12] - The company plans to continue its investment in new product development and market expansion strategies to enhance future performance[78] - The company anticipates significant changes in cumulative net profit compared to the previous year, indicating potential losses[35] Shareholder Information - The total number of shareholders at the end of the reporting period was 35,447[16]

Financial Performance - Guangyu Yuan achieved a net profit of 32.003 million yuan for the year 2020, with a cumulative undistributed profit of -593.4961 million yuan, resulting in no profit distribution for the year[6]. - In 2020, the company's operating revenue was CNY 1,109,430,046.82, a decrease of 8.85% compared to 2019[28]. - The net profit attributable to shareholders was CNY 32,003,001.58, down 75.40% from the previous year[28]. - The basic and diluted earnings per share were CNY 0.07, reflecting a decrease of 73.08% year-on-year[29]. - The weighted average return on equity decreased to 1.35%, down 4.24 percentage points from 2019[29]. - The company's net cash flow from operating activities was CNY -75,524,827.22, indicating a negative cash flow situation[28]. - The gross profit margin decreased by 6.54 percentage points due to rising raw material costs and changes in product sales structure[32]. - The company reported a significant increase in advertising expenses to enhance market penetration, leading to a rise in sales expense ratio[32]. - The company’s total profit and net profit decreased by 88.92% and 78.47%, respectively, compared to the previous year[108]. - The company reported a net cash outflow from operating activities of CNY -75.52 million, compared to CNY -140.82 million in the previous year[103]. Risk Management - The company has not faced any significant risks that could materially impact its operations during the reporting period[10]. - The report includes a risk statement regarding potential future risks, including industry policy changes and market competition intensification[10]. - The company continues to strengthen its internal control system to enhance governance and risk management capabilities[98]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or omissions[4]. - The company has not provided guarantees in violation of decision-making procedures[10]. - There are no non-operational fund occupations by controlling shareholders or related parties reported[8]. Market and Industry Trends - The pharmaceutical industry is expected to recover in the long term despite short-term setbacks caused by the pandemic[56]. - The pharmaceutical manufacturing industry in China saw a year-on-year increase of 5.9% in industrial added value in 2020, with investments in the sector rising by 28.4%[60]. - The government’s healthcare policies and the aging population are expected to create a substantial consumer market for the pharmaceutical industry, indicating a positive growth outlook[61]. - The pharmaceutical industry is characterized by inelastic demand, showing stable growth despite fluctuations caused by external factors like the COVID-19 pandemic[61]. Product Development and R&D - The company has 104 drug registration certificates and 19 patented technologies, indicating a strong product portfolio[41]. - The company has established a strong academic research collaboration with several prestigious universities and medical institutions, resulting in nearly 200 published papers, including 12 in SCI journals[70]. - The company is conducting multiple clinical studies, including those on Ding Kun Dan for endometriosis and Gui Ling Ji for cognitive function disorders, to enhance product clinical value[157]. - The company has 40 ongoing and completed research projects, with a total R&D investment of CNY 47.68 million in 2020[102]. - The company is focused on R&D management, emphasizing technical improvements and new drug development, while collaborating with various universities and medical institutions to enhance product quality and efficacy[96]. Sales and Marketing Strategy - The sales strategy includes collaboration with distributors and agents to expand market reach, particularly in traditional Chinese medicine and health products[52]. - The company implemented a decentralized marketing system and increased online marketing efforts, contributing to a rise in sales expense ratio compared to the previous year[78]. - The company developed nearly 1,000 hospitals during the reporting period, which provided strong support for stable sales growth in hospital terminals and effectively boosted the OTC market[81]. - The company signed contracts with nearly 200 first-level distributors and about 300 second-level distributors, expanding its terminal network coverage[85]. - The company actively adjusted its marketing strategies in response to the pandemic, emphasizing customer retention and sales growth[80]. Financial Position - As of the end of the reporting period, the company's total assets were CNY 3.798 billion, and the net assets attributable to shareholders were CNY 2.412 billion[78]. - The company reported an increase in cash and cash equivalents by 155.34 million yuan, representing a growth of 65.18%, primarily due to an increase in bank acceptance bill deposits by 168 million yuan[64]. - Inventory decreased by 161.65 million yuan, a reduction of 30.83%, mainly due to a decrease in the company's stock of goods and raw materials[64]. - The company’s long-term borrowings amounted to 26 million yuan, with a 100% increase in the current period[138]. - The company’s financial expenses decreased by 16.81% to 28.69 million yuan due to reduced bank acceptance bill discounting costs[128]. Product Performance - The company’s core products include four major varieties, with significant recognition in traditional Chinese medicine, including being listed as national intangible cultural heritage[66]. - The company’s product fingerprint consistency rate exceeds 92%, ensuring high quality control of traditional Chinese medicine products[71]. - The company’s revenue from the Internal Medicine category was 21,381.93 million RMB, reflecting a decrease of 38.80% compared to the previous year, with a gross margin of 89.11%[189]. - The company’s revenue from the Gynecology category was 31,538.43 million RMB, down 41.54% year-on-year, with a gross margin of 74.45%[189]. - The company’s revenue from Health Wine was 2,081.12 million RMB, reflecting a significant decrease of 64.34% compared to the previous year[189]. Regulatory Environment - Recent regulatory policies from the National Medical Products Administration are expected to create both challenges and opportunities for the company in the Chinese medicine sector[160]. - The new drug registration management measures implemented on July 1, 2020, emphasize the management functions of drug registration and clarify departmental responsibilities[164]. - The National Medical Insurance Bureau has implemented a new selection process for drug adjustments, focusing on essential medicines and ensuring controllable expenditures of the medical insurance fund[175]. Future Outlook - The company aims to leverage policy opportunities to gain a larger market share in the traditional Chinese medicine sector[162]. - The company is committed to enhancing its research and development capabilities in response to the evolving regulatory landscape[166]. - The company is focused on sustainable development by leveraging its brand, product, and research advantages[169].

Financial Performance - Net profit attributable to shareholders of the listed company was CNY 64,842,641.70, a decrease of 62.69% year-on-year[9]. - Operating revenue for the period was CNY 686,946,143.57, down 19.58% from the same period last year[9]. - The weighted average return on net assets decreased to 2.71%, down 4.69 percentage points from the previous year[9]. - Basic earnings per share were CNY 0.13, a decline of 62.86% compared to CNY 0.35 in the previous year[9]. - Total profit decreased by CNY 149.37 million, a decline of 69.54%, primarily due to a 19.58% decrease in sales revenue impacted by the COVID-19 pandemic[28]. - Net profit decreased by CNY 119.96 million, a decline of 65.45%, attributed to increased marketing and advertising expenses[28]. - Net profit for Q3 2020 was approximately ¥20.61 million, compared to ¥59.13 million in Q3 2019, indicating a decline of 65.06%[63]. - The total comprehensive income for Q3 2020 was approximately ¥20.61 million, a decrease of 65.06% from ¥59.13 million in Q3 2019[66]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,902,020,278.76, an increase of 10.31% compared to the end of the previous year[9]. - Total liabilities increased to ¥1,399,406,473.43 from ¥1,095,580,771.58, reflecting a growth of approximately 28%[43]. - Owner's equity attributable to shareholders rose to ¥2,421,779,060.77 from ¥2,356,936,419.07, an increase of about 3%[46]. - Total non-current assets amounted to ¥950,445,557.66, unchanged from the previous period[95]. - Current liabilities totaled ¥1,056,147,465.83, with short-term borrowings at ¥173,427,800.00[98]. - The total equity of the company stands at 2,757,215,951.38, with an accumulated deficit of -581,890,616.30[112]. Cash Flow - Net cash flow from operating activities was CNY -163,450,467.38, compared to CNY -128,679,933.87 in the same period last year[9]. - Cash flow from operating activities for the first three quarters of 2020 was negative CNY 163,450,467.38, compared to negative CNY 128,679,933.87 in the same period of 2019[78]. - The total cash inflow from operating activities was ¥877,949,411.22, significantly higher than ¥445,772,491.35 in the previous year, indicating a growth of 96.8%[85]. - The company experienced a net cash outflow from investment activities of ¥33,233,750.99, compared to a smaller outflow of ¥26,095.18 in 2019[87]. - Cash flow from financing activities showed a net inflow of ¥123,138,211.41, down from ¥207,040,392.92 in the previous year, reflecting a decrease of 40.5%[88]. Shareholder Information - The total number of shareholders at the end of the reporting period was 32,369[12]. - The top shareholder, Xi'an Dongsheng Group Co., Ltd., held 63,693,726 shares, accounting for 12.95% of the total shares[12]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 22,977,411.34 from the beginning of the year to the end of the reporting period[12]. - The company reported a total non-operating income and expenses of CNY 18,651,542.92 for the year-to-date[12]. - The company reported other income of CNY 533,355.56 in Q3 2020, significantly higher than CNY 40,704.00 in Q3 2019[71]. Investments and Expenditures - Development expenditures increased by CNY 14.22 million, a growth of 299.55%, mainly due to increased investment in clinical efficacy and pharmacology for specific products[25]. - Long-term equity investments increased to ¥7,752,568.66 from ¥6,266,889.38, a growth of approximately 24%[40]. - Other equity instrument investments rose to ¥22,350,000.00 from ¥17,350,000.00, reflecting a 29% increase[40]. Changes in Accounting and Financial Standards - The company implemented a new revenue recognition standard starting January 1, 2020, adjusting prepayments to contract liabilities[101]. - The company has adjusted its financial statements to reflect the new revenue recognition standards effective from January 1, 2020, moving prepayments to contract liabilities[113].

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 432,558,335.54, a decrease of 20.11% compared to the same period last year[23]. - The net profit attributable to shareholders was CNY 43,440,688.96, down 62.96% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was CNY 26,927,054.37, a decrease of 73.07% compared to the previous year[23]. - The basic and diluted earnings per share were CNY 0.09, a decline of 64.00% year-on-year[24]. - The weighted average return on net assets was 1.83%, down 3.16 percentage points from the previous year[24]. - The company's cash flow from operating activities was negative CNY 126,559,912.53, compared to negative CNY 78,477,209.17 in the same period last year[23]. - The company's total profit decreased by 69.54% to CNY 43,863,446.83, down from CNY 144,019,935.08 in the same period last year[82]. - The company reported a revenue of 432.56 million yuan for the period, a year-on-year decrease of 20.11%, and a net profit attributable to shareholders of 43.44 million yuan, down 62.96%[67]. Assets and Liabilities - The company's total assets increased by 8.52% to CNY 3,838,683,719.53 compared to the end of the previous year[23]. - As of June 30, 2020, the company's total assets were 3,838.68 million yuan, and the equity attributable to shareholders was 2,400.38 million yuan[67]. - The total liabilities as of June 30, 2020, were RMB 1,354,178,212.05, compared to RMB 1,095,580,771.58 at the end of 2019, representing an increase of about 23.6%[186]. - The equity attributable to shareholders of the parent company increased to RMB 2,400,377,108.03 from RMB 2,356,936,419.07, reflecting a growth of approximately 1.8%[189]. Marketing and Sales Strategy - The company increased its marketing and advertising expenses by CNY 9,717,200, impacting the sales expense ratio[27]. - The sales structure change led to a decrease in the revenue proportion of high-margin products, affecting the overall gross margin, which fell by 3.34 percentage points[27]. - The traditional Chinese medicine segment generated 326.15 million yuan in revenue, accounting for 75% of total revenue, with the product An Gong Niu Huang Wan achieving a record sales of 156 million yuan[69]. - The company established a medical department for An Gong Niu Huang Wan, gaining support from 81 new hospitals after its inclusion in the national COVID-19 treatment plan[70]. - The company is actively exploring online sales channels and digital marketing strategies to counteract the negative impacts of the pandemic on traditional sales[116]. Research and Development - The company invested ¥1.07 million in R&D for clinical efficacy and pharmacology related to its key products, along with ¥182,140 for the "Zhiliao APP" project[97]. - The company has 19 patented technologies and 175 trademarks, showcasing its strong intellectual property portfolio[36]. - The company has published nearly 180 papers in domestic and international journals, including 8 papers indexed by SCI, enhancing the clinical value and market competitiveness of its products[60]. Risk Factors - The company faced various risks including market competition and the impact of the COVID-19 pandemic, which were detailed in the report[7]. - The company plans to strengthen its focus on traditional Chinese medicine, premium products, and health-related offerings to mitigate risks and enhance sustainable development[108]. - The COVID-19 pandemic has led to a significant reduction in foot traffic at pharmacies and hospitals, adversely affecting sales of non-epidemic related products[116]. Environmental Compliance - The company’s wastewater discharge includes a CODCr average concentration of 89 mg/L, with a total discharge of approximately 0.534 tons, meeting the A standard of the relevant regulations[142]. - The company’s air emissions include a dust discharge of approximately 0.044 tons, complying with the comprehensive emission standards for air pollutants[143]. - The company conducts regular third-party environmental monitoring to ensure compliance with discharge standards[150]. Corporate Governance - The company confirmed that there are no major litigation or arbitration matters during the reporting period[125]. - The company’s actual controller and related parties have committed to minimizing related party transactions and ensuring fairness in dealings with the company[122]. - The company has not faced any penalties or corrective actions from regulatory authorities during the reporting period[128].

Financial Performance - The company reported a net profit attributable to shareholders of 130.07 million RMB in 2019, a decrease of 65.23% compared to 374.11 million RMB in 2018[27]. - Total revenue for 2019 was 1.22 billion RMB, down 24.81% from 1.62 billion RMB in 2018[27]. - The net cash flow from operating activities was -140.82 million RMB, showing an improvement from -297.97 million RMB in 2018[27]. - The net profit decreased by 65.15% year-on-year, totaling ¥137,345,148.45, attributed to reduced sales and increased costs[107]. - The total profit decreased by 65.07% year-on-year, amounting to ¥157,972,880.95, driven by lower sales and increased operational costs[107]. - The company’s sales revenue decreased by 24.81% year-on-year due to macroeconomic downturns and industry policy impacts[99]. - The company reported a significant increase in other income by 468.45%, amounting to ¥4,669,403.55, due to government subsidies[106]. - The company’s revenue from the Internal Medicine category was CNY 34,937.71 million, a decrease of 33.91% compared to the previous year, with a gross margin of 92.19%[200]. - The revenue from the Gynecology category was CNY 53,944.47 million, showing a slight decrease of 1.90% year-on-year, with a gross margin of 75.84%[200]. - The company reported a total revenue of CNY 121,709.75 million, with a gross margin of 77.79%, which is higher than several comparable companies in the industry[200]. Assets and Liabilities - The total assets increased by 14.89% to 3.54 billion RMB at the end of 2019, compared to 3.08 billion RMB at the end of 2018[27]. - The net assets attributable to shareholders rose by 3.03% to 2.36 billion RMB at the end of 2019, up from 2.29 billion RMB at the end of 2018[27]. - Cash and cash equivalents increased to CNY 238.33 million, representing 6.99% of total assets, a 90.40% increase year-on-year[137]. - The company’s inventory rose to CNY 524.32 million, accounting for 15.38% of total assets, reflecting a 40.43% increase from the previous year[137]. Research and Development - The company invested 64.0351 million yuan in R&D during the reporting period, completing 34 R&D projects[95]. - The company’s R&D investment accounted for 5.26% of its operating revenue, slightly above the industry average of 3.37%[193]. - The company completed 3 R&D projects during the reporting period, with 31 ongoing projects, focusing on various studies including non-clinical safety evaluations and clinical trials for its core products[182]. - The R&D investment for the product "Dingkun Dan" for non-clinical safety evaluation and toxicology research was 9.9028 million RMB, accounting for 0.01% of revenue and 0.04% of costs[187]. - The R&D investment for "Gui Ling Ji" capsules for specific clinical trials was 8.8054 million RMB, representing a 37.11% increase compared to the previous year[187]. Market and Sales Strategy - The company plans to expand its sales channels into county-level markets to enhance market penetration[31]. - The company’s sales model includes collaboration with distributors, agency sales, and direct sales to retail pharmacies, enhancing market reach[54][55]. - The company signed contracts with over 200 first-level distributors and 520 second-level distributors, ensuring effective coverage of the national commercial network[85]. - The company established long-term partnerships with over 1,000 chain pharmaceutical enterprises, managing nearly 50,000 chain terminal stores[80]. - The company focused on digital marketing transformation and expanded into county-level markets, enhancing operational efficiency[81]. Production and Quality Control - The company maintains strict quality control in production, adhering to national GMP standards and traditional preparation methods[51]. - The company employs a "sales-driven production" model, aligning production plans with sales demand while maintaining a safety stock to prevent shortages[51]. - The company’s unique production techniques, such as traditional methods of processing herbs, provide a competitive edge that is difficult for others to replicate[148]. - The company is committed to the "full industry chain" strategy to build high-quality Chinese medicine, ensuring sustainable and healthy development[155]. Industry Context and Challenges - The pharmaceutical manufacturing industry in China experienced a slowdown, with sales revenue growth at 7.4% in 2019, down from 12.4% in 2018, and profit growth at 5.9%, down from 9.5%[57]. - The new Drug Administration Law implemented in May 2019 emphasizes strict management and penalties for counterfeit drugs, significantly impacting the pharmaceutical industry[152]. - The government’s supportive policies for traditional Chinese medicine are expected to create greater development opportunities for the industry[144]. - The national healthcare reform policies are expected to create significant opportunities for the grassroots medical market, which the company aims to capitalize on[156]. Awards and Recognition - The company received multiple awards, including the "Brand Influence Award" in the pharmaceutical industry and was recognized as a "National Brand Project" by Xinhua News Agency[92]. - The core product, Dingkun Dan, ranked first in the "2019 Annual Comprehensive Statistics Ranking of Non-Prescription Drug Products - Traditional Chinese Medicine - Gynecology" by the China Non-Prescription Drug Association[80]. - The company ranked 42nd in the "2018 Annual Top 100 Traditional Chinese Medicine Enterprises" published by the National Drug Store Week and the China Pharmaceutical Innovation Development Conference[80].

Financial Performance - Net profit attributable to shareholders decreased by 51.89% to CNY 27,573,010.12, primarily due to a 17.10% decline in operating revenue[11] - Operating revenue for the period was CNY 224,906,866.92, down from CNY 271,312,337.59 in the same period last year, a decrease of CNY 46,405,500[11] - Basic and diluted earnings per share fell by 62.50% to CNY 0.06, attributed to an increase in share capital by 13,912,070 shares[11] - The company’s net profit after deducting non-recurring gains and losses decreased by 32.50% to CNY 28,300,739.22[11] - Total profit decreased by 61.04% to CNY 27.64 million, primarily due to a decrease in sales revenue of CNY 46.41 million compared to the previous year[29] - Net profit decreased by 56.23% to CNY 26.89 million, influenced by increased advertising expenses and reduced government subsidies[29] - The company reported a total comprehensive income of CNY 26,892,619.40 for Q1 2020, compared to CNY 61,446,575.03 in Q1 2019, reflecting a significant decline[60] Cash Flow - Net cash flow from operating activities was negative at CNY -96,876,641.76, compared to a positive CNY 11,152,751.53 in the previous year[9] - Operating cash flow net amount decreased by CNY 108.03 million, mainly due to a reduction in cash received from sales[33] - In Q1 2020, the company reported cash inflows from operating activities of approximately ¥185.8 million, a decrease of 47.4% compared to ¥353.2 million in Q1 2019[69] - The net cash flow from operating activities for Q1 2020 was approximately -¥96.9 million, compared to a positive cash flow of ¥11.2 million in Q1 2019[69] - Cash inflows from financing activities in Q1 2020 amounted to approximately ¥176.1 million, compared to ¥301.1 million in Q1 2019[71] - The net cash flow from financing activities for Q1 2020 was approximately ¥93.7 million, a significant improvement from -¥27.9 million in Q1 2019[71] Assets and Liabilities - Total assets increased by 4.88% to CNY 3,710,048,604.14 compared to the end of the previous year[9] - Total liabilities increased to ¥1,241,379,811.47 from ¥1,095,580,771.58, reflecting a growth of approximately 13.3%[41] - Current liabilities totaled ¥1,162,498,775.72, compared to ¥1,056,147,465.83, marking an increase of about 10.1%[41] - The total current assets were reported at ¥533,693,482.13, down from ¥537,399,646.96, showing a decrease of approximately 0.9%[48] - Total liabilities reached ¥1,095,580,771.58 as of January 1, 2020, with current liabilities accounting for ¥1,056,147,465.83[86] Shareholder Information - The total number of shareholders at the end of the reporting period was 27,582[15] - The top shareholder, Xi'an Dongsheng Group Co., Ltd., held 72,864,726 shares, representing a significant portion of the company's equity[15] Expenses - The company reported an increase in advertising expenses by CNY 22,730,200, while government subsidies received decreased by CNY 21,972,100 compared to the previous year[11] - R&D expenses decreased by 48.64% to CNY 61.55 million, mainly due to a slowdown in the progress of certain R&D projects[27] - The company experienced a decrease in sales expenses to CNY 104,635,061.01 in Q1 2020 from CNY 113,015,898.57 in Q1 2019, a reduction of 7.5%[56] Investments - Long-term equity investments increased to ¥8,156,961.07 from ¥6,266,889.38, representing a growth of approximately 30.2% year-over-year[39] - The company invested approximately ¥6.7 million in capital expenditures during Q1 2020, reflecting a strategic focus on long-term growth despite reduced cash flow[71] Equity - The company's equity attributable to shareholders rose to ¥2,384,509,429.19 from ¥2,356,936,419.07, a growth of approximately 1.2%[43] - Total equity as of March 31, 2020, was CNY 2,754,040,622.01, a decrease from CNY 2,757,215,951.38 as of December 31, 2019[52] - The total equity attributable to shareholders was ¥2,356,936,419.07 as of January 1, 2020, showcasing strong financial health[88]

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2019 年第三季度报告 二〇一九年十月二十六日 广誉远中药股份有限公司 2019 年第三季度报告 目 录 | --- | |--------------------| | | | 一、重要提示 . | | 二、公司基本情况 . | | 三、重要事项 . | | 四、 附录 . | 1 广誉远中药股份有限公司 2019 年第三季度报告 单位：元 币种：人民币 一、重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张斌、主管会计工作负责人傅淑红及会计机构负责人（会计主管人员） 侯宽余保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | --- | |-----------------------------------------------|-- ...